RAFAEL HOLDINGS INC-CLASS B (RFL) Stock Price, Forecast & Analysis
NYSE:RFL • US75062E1064
RFL Key Statistics, Chart & Performance
The current stock price of RFL is 1.2 USD. In the past month the price decreased by -3.23%. In the past year, price decreased by -42.31%.
RFL Technical Analysis
RFL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RFL. The financial health of RFL is average, but there are quite some concerns on its profitability.
RFL Financial Highlights
Over the last trailing twelve months RFL reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS increased by 48.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.73% | ||
| ROE | -36.78% | ||
| Debt/Equity | 0.01 |
RFL Forecast & Estimates
RFL Ownership
RFL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RFL
Company Profile
Rafael Holdings, Inc. owns an interest in clinical and early-stage pharmaceutical companies. The company is headquartered in Newark, New Jersey and currently employs 21 full-time employees. The company went IPO on 2018-03-12. The firm's segments include Healthcare, Infusion Technology and Real Estate. The Company’s lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. The Healthcare segment comprises equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Cyclo, and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which comprise a portion of one commercial building in Israel. The Infusion Technology segment comprises equity interests in Day Three Labs, Inc. LipoMedix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company.
Company Info
RAFAEL HOLDINGS INC-CLASS B
520 Broad Street
Newark NEW JERSEY 07102 US
CEO: Ameet Mallik
Employees: 30
Phone: 12126581450
RAFAEL HOLDINGS INC-CLASS B / RFL FAQ
What does RAFAEL HOLDINGS INC-CLASS B do?
Rafael Holdings, Inc. owns an interest in clinical and early-stage pharmaceutical companies. The company is headquartered in Newark, New Jersey and currently employs 21 full-time employees. The company went IPO on 2018-03-12. The firm's segments include Healthcare, Infusion Technology and Real Estate. The Company’s lead candidate is Trappsol Cyclo, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (NPC1), a rare, fatal and progressive genetic disorder. The Healthcare segment comprises equity interests in LipoMedix Pharmaceuticals Ltd., Barer Institute Inc., Cornerstone Pharmaceuticals, Inc., Cyclo, and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which comprise a portion of one commercial building in Israel. The Infusion Technology segment comprises equity interests in Day Three Labs, Inc. LipoMedix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company.
Can you provide the latest stock price for RAFAEL HOLDINGS INC-CLASS B?
The current stock price of RFL is 1.2 USD.
What is the dividend status of RAFAEL HOLDINGS INC-CLASS B?
RFL does not pay a dividend.
What is the ChartMill technical and fundamental rating of RFL stock?
RFL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is RAFAEL HOLDINGS INC-CLASS B worth?
RAFAEL HOLDINGS INC-CLASS B (RFL) has a market capitalization of 62.11M USD. This makes RFL a Micro Cap stock.